Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $197.97 million. The enterprise value is $38.87 million.
| Market Cap | 197.97M |
| Enterprise Value | 38.87M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 59.10 million shares outstanding. The number of shares has increased by 55.93% in one year.
| Current Share Class | 59.10M |
| Shares Outstanding | 59.10M |
| Shares Change (YoY) | +55.93% |
| Shares Change (QoQ) | +6.03% |
| Owned by Insiders (%) | 1.71% |
| Owned by Institutions (%) | 76.92% |
| Float | 54.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.97, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.97 |
| Quick Ratio | 10.79 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.80% and return on invested capital (ROIC) is -30.72%.
| Return on Equity (ROE) | -45.80% |
| Return on Assets (ROA) | -28.82% |
| Return on Invested Capital (ROIC) | -30.72% |
| Return on Capital Employed (ROCE) | -47.18% |
| Weighted Average Cost of Capital (WACC) | 12.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.52M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.15% in the last 52 weeks. The beta is 1.49, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -6.15% |
| 50-Day Moving Average | 3.90 |
| 200-Day Moving Average | 4.93 |
| Relative Strength Index (RSI) | 32.83 |
| Average Volume (20 Days) | 863,449 |
Short Selling Information
The latest short interest is 4.43 million, so 7.50% of the outstanding shares have been sold short.
| Short Interest | 4.43M |
| Short Previous Month | 4.54M |
| Short % of Shares Out | 7.50% |
| Short % of Float | 8.08% |
| Short Ratio (days to cover) | 12.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -76.79M |
| Pretax Income | -70.02M |
| Net Income | -70.02M |
| EBITDA | -76.45M |
| EBIT | -76.79M |
| Earnings Per Share (EPS) | -$1.35 |
Balance Sheet
The company has $142.49 million in cash and $2.75 million in debt, with a net cash position of $159.10 million or $2.69 per share.
| Cash & Cash Equivalents | 142.49M |
| Total Debt | 2.75M |
| Net Cash | 159.10M |
| Net Cash Per Share | $2.69 |
| Equity (Book Value) | 161.31M |
| Book Value Per Share | 2.73 |
| Working Capital | 132.83M |
Cash Flow
In the last 12 months, operating cash flow was -$66.13 million and capital expenditures -$360,000, giving a free cash flow of -$66.49 million.
| Operating Cash Flow | -66.13M |
| Capital Expenditures | -360,000 |
| Depreciation & Amortization | 343,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -66.49M |
| FCF Per Share | -$1.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TARA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -55.93% |
| Shareholder Yield | -55.93% |
| Earnings Yield | -35.00% |
| FCF Yield | -33.24% |
Analyst Forecast
The average price target for TARA is $25.71, which is 667.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.71 |
| Price Target Difference | 667.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |